上 市 公 司 家用电器 | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 2.07 | | 资产负债率% | 56.53 | | 总股本/流通 A 股（百万） | 611/464 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 09-24 10-24 11-24 12-24 01-24 02-24 03-24 04-24 05-24 06-24 07-24 08-24 09-24 0% 10% 20% 30% 40% 开能健康 沪深300指数 (收益率) 相关研究 证券分析师 刘正 A0230518100001 liuzheng@swsresearch.com 刘嘉玲 A0230522120003 liujl@swsresearch.com 2025 年 09 月 25 日 开能健康 (300272) ——点评：打造细胞产业为公司第二曲线，主业稳健增长 报告原因：有信息公布需要点评 增持（维持） | 市场数据： | 2025 年 09 月 24 日 | | --- | --- | | 收盘价（元） | 6.46 ...

Group 1 - The company plans to establish a wholly-owned subsidiary in Hainan or Hunan provinces to engage in the cell industry and related mergers and acquisitions [1] - The registered capital for the new subsidiary will be 100 million yuan [1] - This move aims to strengthen the company's positioning in the cell industry and create a second growth curve for the company [1]

Core Viewpoint - Yuaneng Bio has officially launched its Series B financing and is actively preparing for its listing on the Sci-Tech Innovation Board, focusing on the automation of low-temperature storage technology for nearly eight years [1][5]. Group 1: Company Development and Innovations - The company has applied for over 600 domestic and international patents, with more than 500 granted as of December 2024 [1]. - Yuaneng Bio aims to innovate and industrialize low-temperature storage technology, moving from laboratory applications to broader industrial use, driven by policy, capital, and entrepreneurial efforts [1][5]. - The company has invested nearly 800 million yuan in the development of advanced automated low-temperature storage equipment [2]. Group 2: Product and Market Strategy - Yuaneng Bio has developed a series of automated deep low-temperature biological sample storage devices, achieving a breakthrough from 0 to 1 in research and development [3]. - The company is currently in the small-batch manufacturing phase, focusing on standardizing and modularizing its products to reduce production costs [3]. - Yuaneng Bio has successfully implemented its automated equipment in various projects, including those with the Chinese CDC and several hospitals [2]. Group 3: Future Outlook and Expansion - The company plans to enhance its global presence while deepening its domestic market engagement, with a focus on expanding its customer base internationally [3]. - Yuaneng Bio's Orcella Instruments brand won the "Outstanding New Product Award" at the ISBER awards in Canada, highlighting its international recognition [3]. - The company is set to complete a smart manufacturing base in Shanghai in 2024, covering nearly 10,000 square meters, to support its production capabilities [5].